CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The ViVac project is developing a new carbohydrate-based adjuvant, Viscogel, for use in vaccines. It aims to enhance immune responses in both prophylactic and therapeutic applications, particularly for common infectious diseases and allergies.
The overall aim of the ViVac project is to develop and to show safety and efficacy for a new innovative carbohydrate (chitosan) based adjuvant -Viscogel –to be used both in prophylactic and therapeutic vaccination.
Three SME participants will contribute with their specific technologies: the unique Viscogel technology, a specific type of cationic peptides with cell-penetrating capacity (LTX) and a technology platform for production of recombinant allergens (Bet v 1).
Viscogel has excellent adjuva…
Viscogel AB
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Norway, Tromso
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Spain, Madrid
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Norway, Trondheim
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Türkiye, Cankaya Ankara
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
